Program News
News and stories about the UNC Lineberger Gastrointestinal Oncology Program
-
New blood test for colorectal cancer: what you need to know
A new test can detect colorectal cancer with a simple blood draw. However, a colonoscopy is still more reliable and effective than newer screening methods.
-
A call for more data on watch and wait approach for some rectal cancer cases
In a commentary in JAMA Oncology, José Gaston Guillem, MD, MPH, MBA, FACS, FASCRS, cautions against the rush to extend the treatment approach to patients whose cancer has nearly, but not completely, responded to chemotherapy and radiation therapy.
-
Kim named to new leadership roles in Department of Surgery, NC Basnight Cancer Hospital
Hong Jin (HJ) Kim, MD, has been appointed vice chair of academic affairs in the UNC School of Medicine’s Department of Surgery and associate physician-in-chief of the N.C. Basnight Cancer Hospital.
-
Pancreatic Cancer Action Network names Yeh to scientific and medical advisory board
Jen Yeh, MD, has been appointed to the Pancreatic Cancer Action Network’s scientific and medical advisory board, which is comprised of leading scientists, clinicians and healthcare professionals across the United States.
-
UNC Lineberger pancreatic cancer researchers receive five-year, $4.6 million grants from National Cancer Institute
The NCI awarded $9.3 million in support of two five-year research projects from researchers in the UNC Lineberger Pancreatic Cancer Center of Excellence in partnership with other institutions.
-
UNC Lineberger earns National Pancreas Foundation Center of Excellence designation
The designation is in recognition of UNC Lineberger’s multidisciplinary pancreatic cancer care program and its focus on providing the best possible outcomes and an improved quality of life for patients.
-
Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine
Hanna K. Sanoff, MD, MPH, is the author of a viewpoint that provides a perspective on the evolving treatment of rectal cancer in light of findings from a phase II clinical trial using the drug dostarlimab.